Pri-Med Philadelphia

Philadelphia, PA | November 17-18, 2020

Pennsylvania Convention Center


The following financial relationships have been disclosed by faculty: 

Financial Disclosures

Robert H. Hopkins, Jr, MD, MACP, FAAP
No financial disclosures
Pamela Kushner, MD, FAAFP
AstraZeneca, Advisory Board; AstraZeneca, Consultant; AstraZeneca, Speakers Bureau; Bristol-Myers Squibb, Advisory Board; Janssen Pharmaceuticals, Inc., Advisory Board; Janssen Pharmaceuticals, Inc., Consultant; Janssen Pharmaceuticals, Inc., Speakers Bureau; Lilly USA, LLC, Advisory Board; Novo Nordisk Inc., Advisory Board; Pfizer, Advisory Board
Salvatore Mangione, MD
No financial disclosures
Shirah Vollmer, MD
No financial disclosures
Karol E. Watson, MD, PhD
Amarin Pharma Inc., Advisory Board; Amgen, Advisory Board; Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC, Speakers Bureau; Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC., Advisory Board; Esperion, Advisory Board

Other Disclosures

Pamela Kushner, MD, FAAFP (Reviewer):  Advisory Board and Speaker's Bureau for AstraZeneca, GlaxoSmithKline, and Janssen Pharmaceuticals, Inc. (endocrinology, anticoagulation); Consulting Fee and Services Provided for Promotional Purposes for AstraZeneca and Janssen Pharmaceuticals (endocrinology, anticoagulation).

Ty J. Gluckman, MD, FACC, FAHA (Clinical Advisory Board): Expert Witness for Abbvie Inc. and Teva Pharmaceuticals (lipid modifying therapy/dyslipidemia/hypercholesterolemia).

All other non-faculty contributors involved in the planning, development, editing and review of the content have disclosed no relevant financial relationships.